DAVE FIELDS: Open Payments
NPI 1598423964 · MILILANI, HI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,433 in 57 payments from 13 companies in 2025. Trend: 2023 $2,209 · 2024 $1,171 · 2025 $1,433
Food & beverage: $1,433
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 14 | $378 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $341 |
| ABBVIE INC. | 9 | $194 |
| Teva Pharmaceuticals USA, Inc. | 10 | $141 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $140 |
| Janssen Pharmaceuticals, Inc | 3 | $81 |
| E.R. Squibb & Sons, L.L.C. | 1 | $33 |
| Indivior Inc. | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Vanda Pharmaceuticals Inc. | 1 | $22 |
Products named: ARISTADA, VRAYLAR, ABILIFY ASIMTUFII, AUSTEDO XR, CAPLYTA, VIVITROL, INVEGA SUSTENNA, REXULTI.
Industry payments across HI — which companies pay providers there.
